{"groups":[{"description":"Patients receive low-dose carvedilol orally (PO) once daily (QD) or twice daily (BID) for 24 months.","id":"FG000","title":"Arm I (Carvedilol)"},{"description":"Patients receive placebo PO QD or BID for 24 months.","id":"FG001","title":"Arm II (Placebo)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Pregnancy"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"20"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}],"type":"Cardiac Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"89"},{"groupId":"FG001","numSubjects":"93"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"76"}],"comment":"31 participants who did not have a second timepoint assessment of echocardiography were excluded, resulting in 151 analyzable participants.","type":"2nd Timepoint Assessment of Echocardiology Required to be Analyzable"},{"achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"55"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"38"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"196 pts were enrolled (109 pts enrolled with Childrens Oncology Group (COG) and 87 pts enrolled on a pilot study at City of Hope (COH) 182 of those pts started tx (14 excluded: 6 ineligible and 8 pts started tx). (The (109) enrollment number in the protocol section reflects the number of pts enrolled on the COG portion of the study. Per Section 9.2 of the protocol (pt accrual and expected duration of the trial), 87 pts had already been accrued through a different mechanism the pilot study)"}